Related Experiment Video
Updated: Aug 17, 2026

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
Published on: November 26, 2015
Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer
Jian Zhou1, Jessica Scholes, Jer-Tsong Hsieh
1Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA.
Abstract:
DOC-2/DAB2 is a potent tumor suppressor in many cancer types including prostate cancer. In prostate cancer, expression of DOC-2/DAB2 can inhibit its growth. Our recent studies demonstrate that DOC-2/DAB2 can suppress both protein kinase C and peptide growth factor-elicited signal pathways via the Ras-mitogen-activated protein kinase pathway. In this study, we further showed that the proline-rich domain of DOC-2/DAB2 could also interact with proteins containing the Src homology 3 domain, such as Src and Fgr. The binding of c-Src to DOC-2/DAB2 was enhanced in cells treated with growth factor, and this interaction resulted in c-Src inactivation. The c-Src inactivation was evidenced by the decreased tyrosine 416 phosphorylation of c-Src and reduced downstream effector activation. It appears that DOC-2/DAB2 can bind to Src homology 3 domain of c-Src and maintain it in an inactive conformation. Thus, this study provides a new mechanism for modulating c-Src in prostatic epithelium and cancer.
Insights
DOC-2/DAB2, a tumor suppressor, inhibits prostate cancer growth by interacting with c-Src. This interaction inactivates c-Src, providing a new mechanism for controlling prostatic cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- DOC-2/DAB2 acts as a tumor suppressor in various cancers, including prostate cancer.
- DOC-2/DAB2 inhibits prostate cancer growth by modulating protein kinase C and growth factor signaling pathways via the Ras-MAPK pathway.
Purpose of the Study:
- To investigate the interaction between DOC-2/DAB2 and Src homology 3 (SH3) domain-containing proteins.
- To elucidate the mechanism by which DOC-2/DAB2 modulates c-Src activity in prostate cancer cells.
Main Methods:
- Co-immunoprecipitation assays to study protein-protein interactions.
- Western blotting to assess protein phosphorylation and activation levels.
- Analysis of c-Src activity through phosphorylation at tyrosine 416 and downstream effector activation.
Main Results:
- The proline-rich domain of DOC-2/DAB2 interacts with SH3 domain-containing proteins, including c-Src and Fgr.
- Growth factor stimulation enhances the binding of c-Src to DOC-2/DAB2.
- This interaction leads to the inactivation of c-Src, evidenced by decreased phosphorylation at Tyr416 and reduced downstream signaling.
Conclusions:
- DOC-2/DAB2 binds to the SH3 domain of c-Src, maintaining it in an inactive conformation.
- This study reveals a novel mechanism for regulating c-Src activity in the prostatic epithelium and prostate cancer.
Related Concept Videos
Negative Regulator Molecules
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

